View descriptions of the many Science & Innovation Theaters taking place at ENDO 2024!
Saturday, June 1
10:00-11:00 AM ET
Theater #2
Sponsor Alexion, AstraZeneca Rare Disease
Spotlight on Hypophosphatasia: Shining a Light on Your Adult Patients
Description: Hypophosphatasia (HPP) is a rare, inherited, metabolic disorder caused by tissue-nonspecific alkaline phosphatase (TNSALP) deficiency. In adult patients with HPP, commonly reported symptoms include musculoskeletal pain, recurrent and poorly healing fractures, and dental abnormalities. Due to the variability of the clinical presentation, the diagnosis is often missed or delayed for up to 25 years before an adult patient may receive an HPP diagnosis.
During the product theater, Dr. Rosen will provide a general introduction to HPP and moderate the overall discussion while Dr. Dahir will emphasize the importance of recognizing HPP in adults (and not solely in children) and the evolving landscape of diagnosis in adults with HPP. With a goal to improve healthcare professionals’ diagnosis of HPP and drawing on the latest research and support tools, Dr. Dahir will discuss when to suspect HPP, the challenges of diagnosing HPP, which tests to prioritize, the importance of early detection, and the profound impact on patient outcomes. She will present cases that exemplify the diagnostic journey in adult patients, focusing on both skeletal, as well as non-skeletal manifestations, and discuss lessons learned for future practice.
Speakers:
Kathryn Dahir, MD
Vanderbilt University Medical Center, Nashville, TN
Clifford Rosen, BS, MD
Maine Medical Center’s Research Institute, Scarborough, ME
Saturday, June 1
12:30-1:30 PM ET
Theater #1
Sponsor: Eli Lilly and Company
Mounjaro® (tirzepatide) Product Theater
Description: Join a presentation from one of your peers to learn about Mounjaro, a glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist indicated to improve glycemic control in adults with type 2 diabetes (T2D). This presentation will include a review of clinical efficacy and safety results, and how to get your adult patients with T2D started on Mounjaro. Attendees will have the opportunity to pose questions to the speaker at the end of the session.
Please see the Important Safety Information for Mounjaro, including Boxed Warning about possible thyroid tumors, including thyroid cancer, the Full Prescribing Information, and Medication Guide provided at the product theater.
This program is sponsored by, and the speaker is presenting on behalf of, Lilly USA, LLC. It is being presented consistent with FDA guidelines and is not approved for continuing education credit.
Speaker:
Mark Warren, MD, FACE
Saturday, June 1
12:30-1:30 PM ET
Theater #2
Sponsor: Corcept Therapeutics
Perspectives in Hyperglycemia Secondary to Hypercortisolism – A Path to Diagnosis
Description: Case-based panel discussion on evolving perspectives in endogenous Cushing Syndrome
Speakers:
Richard Auchus, MD, PhD
Professor of Internal Medicine and Endocrinology
University of Michigan
Ann Arbor, MI
James W Findling MD
Professor of Medicine and Surgery
Division of Endocrinology and Molecular Medicine
Medical College of Wisconsin
Milwaukee, WI
Jennifer E. Rosen, MD, FACS
Regional Chief, Endocrine Surgery
Medstar Washington Hospital Center
Associate Professor of Surgery
Georgetown University School of Medicine
Washington, DC
Saturday, June 1
12:30-1:30 PM ET
Theater #3
Sponsor: Acella Pharmaceuticals
Treating Hypothyroidism: Two Researchers’ Perspectives on the Changing Landscape of Hypothyroidism Treatment
Description: Join international experts Elizabeth McAninch, MD and Thanh Hoang, DO, FACP, FACE as they discuss their scientific journeys that led them to focus on hypothyroidism and the patient with persistent clinical symptoms.
Speakers:
Elizabeth A. McAninch, MD
Clinical Associate Professor, Medicine
Stanford University School of Medicine
Palo Alto, CA
Thanh D. Hoang, DO, FACP, FACE
Program Director, NCC Endocrinology Fellowship Program
Professor, Uniformed Services
University of the Health Sciences
Division Director, Endocrine Division
Uniformed Services University of the Health Sciences
Bethesda, MD
Saturday, June 1
3:15-4:15 PM ET
Theater #1
Sponsor: Recordati Rare Diseases, Inc
Examining the Puzzle of Cushing Disease
Description: This interactive panel discussion highlights key topics in Cushing disease, based on feedback from a survey of endocrinologists.
Moderator:
Atil Kargi, MD
Professor of Neurosurgery and Medicine, Co-Director of Pituitary Center in Department of Neurosurgery
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina
Speakers:
Oksana Hamidi, DO
Associate Professor, Division of Endocrinology and Metabolism
University of Texas Southwestern Medical Center
Dallas, Texas
Catherine D Zhang, MD
Assistant Professor of Medicine, Division of Endocrinology and Molecular Medicine Medical College of Wisconsin
Milwaukee, Wisconsin
Saturday, June 1
3:15-4:15 PM ET
Theater #2
Sponsor: Crinetics Pharmaceuticals
Paltusotine: A Novel, Investigational Oral Small Molecule Somatostatin Receptor Ligand for Acromegaly
Description: Acromegaly is a rare chronic disease almost always caused by a pituitary adenoma that secretes excess growth hormone, resulting in hypersecretion of IGF-I, predominantly by the liver. Medical therapy is recommended when surgery fails to achieve remission and for patients who are not suitable candidates for surgery. Somatostatin receptor ligands (SRLs), octreotide and lanreotide, administered by injection are first-line medical treatment for acromegaly. However, there are treatment challenges and high burden of treatment with currently available SRLs. These include poor symptom control, specifically worsening of symptoms at the end of each injection cycle, as well as treatment-related injection site reactions and pain associated with monthly injections often administered in a doctor’s office. There is a clear need for new reliable treatment options that reduce the burden of care for patients. This program will discuss paltusotine, a novel, investigational once-daily, oral, selectively targeted nonpeptide SRL. Results from the PATHFNDR-1 Phase 3 study in patients with acromegaly switched from injected SRL monotherapy to once-daily oral paltusotine will be presented. Paltusotine is an investigational drug and has not yet been filed or approved for marketing authorization.
Speaker:
Kevin C.J. Yuen, MBChB, MD, FRCP, FACE
Barrow Neurological Institute, Phoenix, AZ
Saturday, June 1
3:15-4:15 PM ET
Theater #3
Sponsor: Sanofi TZIELD
Explore Advancements in Type 1 Diabetes Management
Description: Type 1 diabetes (T1D) can have a devastating impact on both patients and their loved ones. Explore advancements in T1D management and the importance of proactive screening, particularly among individuals at increased risk for T1D. Join us to learn more about the paradigm shift in caring for patients with T1D.
Speaker:
Jason Baker, MD
Weill Cornell Medicine
New York, NY
Sunday, June 2
9:30-10:30 AM ET
Theater #1
Sponsor: Tolmar Inc.
The State of TRT: Feeling the impact of trends in practice and patient care
Description: Join us for a presentation and discussion on the results of an inaugural landmark TRT Sermo survey of 303 Endocrinologists, Urologists, PCPs and other specialists sponsored by JATENZO® (testosterone undecanoate) capsules.
Leading experts will explore key testosterone replacement therapy (TRT) insights, trends and common myths for endocrinologists and other specialties, including:
This presentation is funded by, and is being presented on behalf of, Tolmar Pharmaceuticals, Inc. (“Tolmar”). All information about any Tolmar Product is consistent with approved product labeling. This program is not approved for CME credits.
Speakers:
Dr. Adrian Dobs, MD MHS
Division of Endocrinology, Diabetes and Metabolism, The Johns Hopkins University School of Medicine
Baltimore, MD
Dr. Sandeep Dhindsa, M.B.B.S
Chief, Division of Endocrinology and Metabolism, Saint Louis University
SLUCare Academic Pavilion
St. Louis, MO
Sunday, June 2
9:30-10:30 AM ET
Theater #2
Sponsor: Ascendis Pharma A/S
Perspectives on a once-weekly growth hormone for pediatric growth hormone deficiency
Description: A physician speaker will review the clinical data and differentiating features of a once-weekly growth hormone used to treat pediatric growth hormone deficiency. Following the clinical presentation, a caregiver ambassador will tell their child and family’s journey from diagnosis to treatment with a once-weekly growth hormone.
Speaker:
Philippe F. Backeljauw, MD
Consultant, Cincinnati Center for Pediatric and Adult Turner Syndrome Care
Consultant, Center for Growth Disorders
Professor, UC Department of Pediatrics
Sunday, June 2
9:30-10:30 AM ET
Theater #3
Sponsor: Rhythm Pharmaceuticals
Acquired Hypothalamic Obesity: A Distinct, Form of Obesity Associated with MC4R Pathway Impairment.
Description: One hour symposium to educate attendees on the melanocortin-4 receptor (MC4R) pathway, its role in certain rare forms of obesity, and the treatment journey of patients with hypothalamic obesity: an acquired form of obesity distinct from general obesity.
Speakers:
Dr. Susan Phillips, MD
Dr. Vidhu Thaker, MD
Sunday, June 2
12:00-1:00 PM ET
Theater #1
Sponsor: Pfizer
Pfizer’s Latest LAGH in pGHD Treatment: A Clinical Overview and Deep Dive into IGF-1 Monitoring
Description: Pfizer has been committed to the pediatric growth hormone deficiency (pGHD) community for over 30 years. We welcome you to learn more about Pfizer’s latest advancement in pGHD Treatment and how to appropriately interpret patients' IGF-1 levels for it its once-weekly dosing regimen.
Speakers:
Lawrence A. Silverman, MD
Board Certified Pediatric Endocrinologist
Atlantic Medical Group
Morristown Medical Center
Overlook Medical Center
Morristown, NJ
Aristides K. Maniatis, MD, FAAP
Board Certified Pediatric Endocrinologist
Presbyterian/St. Luke’s Medical Center
Swedish Medical Center
Rocky Mountain Pediatric Endocrinology
Centennial, CO
Sunday, June 2
12:00-1:00 PM ET
Theater #2
Sponsor: Dexcom
Maximizing Dexcom's Potential: Advancing Diabetes Care in Type 1 and Type 2 Diabetes
Description: In the swiftly evolving landscape of healthcare technology and accessibility, the care of diabetes can be even more personalized. This program is designed to inform healthcare professionals about the revolutionary role that real-time continuous glucose monitoring (RT-CGM) plays in enhancing diabetes management.
Come join us for an insightful presentation where we explore the cutting-edge developments in Dexcom CGM in T1D and T2D. We'll provide a comprehensive overview of the current commercially available Dexcom-enabled AID systems, explore Dexcom G7, and discuss real-world research findings.
Discover how RT-CGM can be an integral part of diabetes management to help improve glycemic outcomes and support customizable treatment options for your patients.
Professor of Medicine, Division of Endocrinology & Metabolism
Director of Diabetes Clinical Research, IU Center for Diabetes and Metabolic Diseases
Dr. Halis Kaan Akturk MD
Associate Professor of Medicine and Pediatrics
Barbara Davis Center for Diabetes, University of Colorado
Sunday, June 2
12:00-1:00 PM ET
Theater #3
Sponsor: AMGEN
Thyroid Eye Disease (TED): Early Diagnosis and Treatment
Description: Learn about the heterogeneous presentation of Thyroid Eye Disease (TED), importance of early identification, and how endocrinologists can contribute to the care of patients with TED in the evolving treatment landscape.
Speaker:
Todd Frieze
Sunday, June 2
2:30-3:30 PM ET
Theater #1
Sponsor: Kyowa Kirin
Recognizing the Rare: X-Linked Hypophosphatemia (XLH) Diagnosis and Patient Perspectives
Description: X-linked hypophosphatemia (XLH) is a rare genetic metabolic bone disease that often involves a long road to diagnosis and management. Early diagnosis and management in adults with XLH is critical to skeletal health. Join us for a discussion of the hallmark features of XLH, the importance of screening for low phosphorus, and management of XLH.
This product theater is sponsored by Kyowa Kirin, Inc. This presentation is intended for US-based health care providers.
Speakers:
Faculty Presenter:
Dr. Laila Tabatabai, MD
Associate Professor of Clinical Medicine, Academic Institute Houston Methodist
Weill Cornell Medical College Houston, TX
Patient Ambassador:
Aly
San Antonio, TX
Sunday, June 2
2:30-3:30 PM ET
Theater #2
Sponsor: Alexion, AstraZeneca Rare Disease
An Overview of Hypophosphatasia (HPP)
Description: Recognize the signs, symptoms, and burden of hypophosphatasia, as well as the importance of a timely diagnosis
Speaker:
Eric T. Rush, MD, FAAP, CCD
Clinical Geneticist
Underdown/Yeomans Endowed Professor Medical Director
Children's Mercy Hospital, University of Kansas Health System
Kansas City, MO
Sunday, June 2
2:30-3:30 PM ET
Theater #3
Sponsor: Ionis Pharmaceuticals
Familial Chylomicronemia Syndrome (FCS): recognizing, diagnosing, and managing an overlooked genetic form of severe hypertriglyceridemia (sHTG)
Description:
FCS is a debilitating condition that often subjects patients to frequent bouts of pancreatitis, abdominal pain, and a host of other severe symptoms. The impact isn’t just physical; people with FCS also experience a serious psychosocial burden due to anxiety and uncertainty about diet and treatment, difficulty remaining employed, and restricted social lives. This presentation will educate providers on the mechanism of disease behind FCS, how to distinguish FCS from other forms of severe hypertriglyceridemia (sHTG), and current management strategies for this underdiagnosed disease.
Speaker:
Henry N. Ginsberg, MD
Irving Professor of Medicine
Past Director
Irving Institute for Clinical and Translational Research
Columbia University Vagelos College of Physicians and Surgeons
Monday, June 3
9:30-10:30 AM ET
Theater #1
Sponsor: Immunovant
Unmet Needs in Grave’s Disease: Exploring Novel Therapies
Description: Graves’ disease is an autoimmune disease driven by thyroid-stimulating hormone receptor (TSHR) autoantibodies, which can impact multiple organ systems and lead to extra-thyroidal manifestations such as thyroid eye disease (TED). Despite current standard of care, patients may be poorly controlled or relapse, resulting in a negative impact on a patient health and quality of life. Faculty will discuss the current understanding of the pathogenesis of Grave’s Disease and associated TED, burden of disease, disease epidemiology, and unmet patient needs.
Speakers:
Giuseppe Barbesino, MD
Massachusetts General Hospital
Boston, MA
Todd Frieze, MD, FACP, FACE, ECNU
Duke Cancer Center Endocrine Clinic
Durham, NC
George J. Kahaly, MD, PhD
Johannes Gutenberg University Medical Center
Mainz, Germany
Monday, June 3
9:30-10:30 AM ET
Theater #2
Sponsor: Eli Lilly and Company
Discover the Tempo™ Personalized Diabetes Management Platform
Join our product theater to learn about Tempo, a personalized diabetes management platform that combines the Tempo prefilled insulin pen, diabetes management devices, and app-driven support to deliver individualized guidance for adults with diabetes. This presentation will review the challenges to effective diabetes self-management, how Tempo may support healthcare professionals and people with diabetes, and how to start patients with diabetes on Tempo.
Please see the Important Safety Information and Intended Uses for the Tempo Personalized Diabetes Management Platform provided at the product theater.
This program is sponsored by, and the speaker is presenting on behalf of, Lilly USA, LLC. It is being presented consistent with U.S. Food and Drug Administration guidelines and is not approved for continuing education credit.
Speaker:
Joan F. Bailey, MD, BS, FACE, FACP
The University of Arizona College of Medicine – Phoenix
Phoenix, AZ
Monday, June 3
9:30-10:30 AM ET
Theater #3
Sponsor: Novo Nordisk Healthcare AG
Realizing the possibilities: expanding growth hormone treatment options
Description: Growth hormone deficiency is a rare disorder that develops as a result of insufficient secretion of growth hormone (GH). Effects of inadequate GH levels can be significant as GH is required for normal growth in children and for metabolism and body composition in children and adults. This program will discuss the treatment landscape in patients with growth hormone deficiency. The clinical characteristics of a product used to treat patients with growth hormone deficiency will also be presented.
Speakers:
Dr. Heidi C. Shea, MD, F.A.A.P, F.A.C.E
Endocrine Associates of Dallas, PA
Plano, Texas
Dr. Dr. Joshua H. Yang, MD
Orlando Health Arnold Palmer Hospital for Children Endocrinology and Diabetes Center
Orlando, Florida
Monday, June 3
12:30-1:30 PM ET
Theater #1
Sponsor: QuidelOrtho
TSH Receptor Antibodies – Methodological Progress & Clinical Relevance
Description: The role of thyrotropin receptor autoantibodies (TSH-R-Ab) in the pathogenesis of autoimmune hyperthyroidism or Graves’ disease (GD) is well established. Recent advances in biosensors have been applied to the development of TSH-R-Ab bioassays that are rapid and simple to perform. A novel cell-based bioassay, referred to as Turbo TSITM, for measurement of thyroid-stimulating autoantibodies (TSAb) was recently developed. Turbo TSI greatly reduces the complexity and time required to measure TSAb. It avoids the need for cell culture, has no wash or lysis steps, and has a total turn-around-time of less than 90 minutes. Hence, we now are entering an era in which bioassays for TSH-R-Ab can be measured routinely by virtually any clinical laboratory.
Speakers:
Paul D Olivo, MD, PHD
St. Louis, MO, USA
George J Kahaly, MD, PHD
Mainz, Germany
Moderator:
George J Kahaly, MD, PHD
Mainz, Germany
Monday, June 3
12:30-1:30 PM ET
Theater #2
Sponsor: Eli Lilly and Company
Product Theater for Zepbound™ (tirzepatide) Injection
Description: Join a presentation from one of your peers on the efficacy and safety of once-weekly Zepbound, and learn about how to get appropriate patients started on this treatment. Attendees will have the opportunity to pose questions to the speaker at the end of the session. Refreshments will be provided.
Please see the Important Safety Information for Zepbound, including Boxed Warning about possible thyroid tumors, including thyroid cancer, the full Prescribing Information, and Medication Guide provided at the Product Theater.
This program is sponsored by, and the speaker is presenting on behalf of, Lilly USA, LLC. It is being presented consistent with FDA guidelines and is not approved for continuing education credit.
Speaker:
Tamer Yacoub, MD, FACE
Monday, June 3
12:30-1:30 PM ET
Theater #3
Sponsor: Rhythm Pharmaceuticals
Not All Obesity Is the Same: A Look at Rare Neuroendocrine Diseases
Description:
Join us in learning more about some rare Neuroendocrine Diseases that patients are born with resulting for genetic mutations in a critical brain pathway: leptin-melanocortin-4 receptor (MC4R) pathway in the hypothalamus. Dr. Paisley is going to talk about the importance of leptin-MC4R pathway in regulation of appetite and energy expenditure, and how loss-of-function variants in this pathway cause early-onset obesity and hyperphagia along with other endocrinopathies. Understanding how hyperphagia is different from other eating disorders, and understanding the symptoms and behaviors associated with hyperphagia can help clinicians diagnose it more accurately. Dr. Paisley will also discuss how MC4R pathway associated obesity is different from general obesity. These neuroendocrine diseases are rare, have multi-organ syndromic presentations requiring different specialists to identify and diagnose, and are progressive in nature. Some of the syndromic conditions are genetic in etiology but clinically diagnosed. This makes it difficult to identify patients that might need genetic testing or further clinical evaluations beyond traditional weight markers. Dr. Paisley will outline a step-by-step algorithm to determine differential diagnosis process. We will discuss the distinctive features of monogenic and syndromic obesity compared to general obesity, with the focus on how patients with rare forms of obesity can be identified, evaluated, and diagnosed in the clinic. We will end with case studies using the algorithm to make efficient diagnosis of MC4R pathway diseases.
Speakers:
Jennifer Paisley, MD, FAAP, Dipl ABOM
Internal Medicine & Pediatrics, St. Elizabeth Health care ( Lawrenceburg, IN)
